Alkadi Turad A, Binyousef Faris Hussam, Alruwaili Shahad A
Department of Ophthalmology, College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia.
Department of Ophthalmology, Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia.
Oman J Ophthalmol. 2025 Jun 24;18(2):138-143. doi: 10.4103/ojo.ojo_225_23. eCollection 2025 May-Aug.
Uncorrected refractive errors are a major global public health concern, responsible for approximately 50% of visual impairments. Surgical options such as photorefractive keratectomy (PRK) and laser keratomileusis (LASIK) are effective but can result in myopic regression, necessitating retreatment. To evaluate the efficacy, safety, and predictability of transepithelial PRK (Trans-PRK) for correction of myopic regression after previous refractive surgery.
Trans-PRK was performed in eyes with myopic regression after previous PRK or LASIK with a mean refractive spherical equivalent (SE) of - 1.92 diopter (D) ±0.96 (standard deviation). The mean preoperative logMAR uncorrected distance visual acuity (UDVA) was 0.59 ± 0.38. Postoperative evaluation included UDVA, SE, epithelial healing, and haze formation at 1 week, 2 months, and 6 months.
The study evaluated 26 eyes of 15 patients. At 6 months postoperatively, the proportion of eyes within ± 0.50 D and ± 1.00 D of the target refraction was 37.5% and 100%, respectively. After the enhancement, the percentage of eyes with Snellen UDVA of 20/20 or better was 80% at 6 months, while all of the eyes had a Snellen UDVA of 20/25 or better. The mean postoperative SE was - 1.01 ± 0.74, at 1 week, -0.61 ± 0.98 at 3 months, and - 0.38 ± 0.57 at 6 months. No significant complications were noted.
The results of this study indicate that Trans-PRK appears to be safe, effective, stable, and predictable procedure for the treatment of myopic regression after previous PRK or LASIK.
未矫正的屈光不正成为全球主要的公共卫生问题,约占视力损害的50%。诸如准分子激光角膜切削术(PRK)和准分子原位角膜磨镶术(LASIK)等手术方法虽有效,但可能导致近视回退,需要再次治疗。目的在于评估经上皮PRK(Trans-PRK)矫正既往屈光手术后近视回退的疗效、安全性及可预测性。
对既往接受过PRK或LASIK手术且平均等效球镜度(SE)为-1.92屈光度(D)±0.96(标准差)的近视回退患者实施Trans-PRK手术。术前平均logMAR未矫正远视力(UDVA)为0.59±0.38。术后评估指标包括术后1周、2个月及6个月时的UDVA、SE、上皮愈合情况及 haze形成情况。
本研究共评估了15例患者的26只眼。术后6个月时,目标屈光度±0.50 D和±1.00 D范围内的眼的比例分别为37.5%和100%。强化治疗后,6个月时Snellen UDVA为20/20或更好的眼的比例为80%,而所有眼的Snellen UDVA均为20/25或更好。术后平均SE在1周时为-1.01±0.74,3个月时为-0.61±0.98,6个月时为-0.38±0.57。未观察到明显并发症。
本研究结果表明,Trans-PRK对于治疗既往PRK或LASIK术后的近视回退而言,似乎是一种安全、有效、稳定且可预测的手术方法。